EPA vs DHA: Why the Two Omega-3s Are Not Interchangeable

Walk down the supplement aisle and you will see fish oil bottles advertised by their total omega-3 content. The label might say 1,200 mg of omega-3s per serving, with the EPA and DHA quantities listed in smaller text below — or, in cheaper products, not broken out at all. This presentation treats the two molecules as interchangeable. They are not.

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are both long-chain omega-3 fatty acids derived primarily from marine sources, and they share enough structural similarity that they are often discussed as a single nutrient. But they enter different metabolic pathways, accumulate in different tissues, and produce different physiological effects. The clinical trials that have tested EPA and DHA separately have repeatedly shown that which one you take — and in what ratio — affects the outcome.

Structure Drives Function

EPA is a 20-carbon fatty acid with five double bonds. DHA is a 22-carbon fatty acid with six. The extra two carbons and one double bond change how each molecule behaves in cell membranes. EPA, the shorter and more flexible molecule, integrates rapidly into the membranes of immune cells and serves as a substrate for anti-inflammatory signaling molecules called resolvins and protectins. DHA, the longer and more curved molecule, concentrates preferentially in neural and retinal tissue, where its specific shape supports membrane fluidity in cells that must transmit electrical signals rapidly.

This structural difference is the basis for the divergent clinical profiles. Studies that have measured tissue distribution after supplementation consistently show that EPA accumulates more heavily in serum, platelets, and white blood cells, while DHA dominates in the brain, retina, and sperm cells. The fatty acid composition of the tissue you are trying to influence determines which omega-3 is more useful.

The REDUCE-IT Result

The largest and most consequential omega-3 cardiovascular trial of the past decade was REDUCE-IT, published in the New England Journal of Medicine in 2019. The study randomized 8,179 patients with established cardiovascular disease or diabetes plus elevated triglycerides to either 4 grams per day of icosapent ethyl — a highly purified EPA-only preparation — or placebo, on top of statin therapy.

The result was a 25% reduction in major cardiovascular events in the EPA group over a median follow-up of nearly five years. Cardiovascular death, nonfatal heart attack, nonfatal stroke, coronary revascularization, and unstable angina all declined. The effect size was large enough that the FDA approved icosapent ethyl as a cardiovascular risk-reduction therapy.

What is notable about REDUCE-IT is that it used pure EPA, not a mixed EPA/DHA product. Earlier trials of mixed omega-3 preparations — including the much larger STRENGTH trial, which tested an EPA+DHA combination at the same total omega-3 dose — failed to show cardiovascular benefit. The simplest interpretation is that EPA, on its own, produces the cardiovascular effect, and that DHA either dilutes it or works against it in this context. The mechanism is not fully resolved, but the trial-level evidence is clear: for cardiovascular risk reduction in patients with elevated triglycerides, the formulation matters.

DHA’s Domain: The Brain and Eye

DHA is the dominant omega-3 in neural tissue. It comprises roughly 40% of the polyunsaturated fatty acid content of the cerebral cortex and approximately 60% of the rod photoreceptor outer segments in the retina. This enrichment is not accidental. DHA’s specific molecular shape allows it to support the rapid conformational changes that membrane proteins must undergo to transmit visual and neural signals. No other fatty acid substitutes adequately.

This is why DHA matters most clearly in contexts where brain or retinal development and maintenance are the target. Adequate DHA intake during pregnancy supports fetal brain and visual development, and most prenatal supplement formulations include DHA specifically for this reason. In adults, DHA supplementation has been associated with modest improvements in cognitive function in some — though not all — clinical trials, with the strongest evidence in older adults and in people with very low baseline intake.

The 2015 review by Simon Dyall in Frontiers in Aging Neuroscience analyzed dozens of mechanistic and clinical studies on omega-3s in the brain. The conclusion was that EPA and DHA have distinct but complementary roles in neural tissue. DHA provides the structural substrate; EPA contributes to neuroinflammatory regulation. For mood disorders specifically — major depression is the most studied — meta-analyses have suggested that products with higher EPA-to-DHA ratios (typically 2:1 or greater) produce more consistent antidepressant effects than DHA-dominant formulations. The mechanism is thought to involve EPA’s role in resolving neuroinflammation, which is implicated in the pathophysiology of depression.

The ALA Detour

A common shortcut in omega-3 nutrition is to point at alpha-linolenic acid (ALA), the 18-carbon plant-derived omega-3 found in flaxseed, chia, and walnuts, as a source. The body can convert ALA to EPA and, more inefficiently, to DHA. The problem is the conversion rate. Multiple metabolic studies have measured the efficiency of this conversion in humans. The rate of ALA to EPA conversion is roughly 5-10% in healthy young adults, falling to under 5% in many populations. The rate of ALA to DHA conversion is under 1%.

This means that for a person whose goal is to raise blood and tissue levels of EPA or DHA, eating flaxseed is a poor substitute for eating fatty fish or taking a marine-source supplement. ALA-rich foods have other nutritional virtues, including fiber, lignans, and antioxidants. But framing them as omega-3 sources, in the same sense as salmon or sardines, overstates what they can deliver. The conversion is too inefficient to bridge the gap.

For people who do not consume marine products, algal oil — derived from microalgae that are the original biological source of DHA — provides a direct vegan source of both DHA and, in some formulations, EPA. Algal supplements have been shown in pharmacokinetic studies to raise blood DHA levels comparably to fish-based supplements.

How to Read a Label

The practical implication for choosing an omega-3 product is that you should ignore the total omega-3 figure on the front of the bottle and read the supplement facts panel. The numbers that matter are the milligrams of EPA and the milligrams of DHA per serving. A 1,000 mg fish oil capsule frequently contains only 300 mg of combined EPA + DHA, with the remainder being other fish lipids that have no documented health benefit.

For cardiovascular risk reduction in people with elevated triglycerides, the REDUCE-IT data support high-dose EPA preparations — 2 to 4 grams of EPA daily — under physician supervision. For general health maintenance and adequacy, most public health authorities suggest 250-500 mg of combined EPA + DHA per day for adults, which can be achieved through two to three servings of fatty fish per week or through supplementation.

For pregnancy and lactation, DHA intake of at least 200 mg per day is recommended to support fetal and infant neural development. For depression or mood support, the evidence supports formulations weighted toward EPA — though the broader evidence on omega-3s as a standalone treatment for depression remains mixed.

The point is not that one fatty acid is universally superior. It is that the question “should I take omega-3s?” is not specific enough to answer well. The better question is which omega-3, at what dose, for what target — and the answers diverge.

Dr. Michael Torres is the Food Chemistry Columnist at Daily Bite Lab. He holds a PhD in Food Science from Cornell University, with research focused on lipid biochemistry and nutrient bioavailability.